Comprehensive regression analysis of hepatitis B virus X antigen level and anti-HBx antibody titer in the sera of patients with HBV infection.
Although the pathogenetic significance of hepatitis B virus x protein (HBxAg) in chronic hepatitis, liver cirrhosis, and primary hepatocellular carcinoma has already been studied, the comparative analyses of both the actual serum HBxAg levels and antibody production against various HBx epitopes have been examined to lesser extent. We have simultaneously investigated the relationship between antibody production (IgG and IgM) against the HBxAg fragments and HBxAg level in the sera of patients with acute (14) or chronic hepatitis (80) and symptomless carriers (12). A recently developed sandwich-type ELISA was used for the quantitative measurements of HBxAg. Overlapping recombinant and synthetic antigens were used to map the fine epitope specificities of circulating anti-HBx antibodies. In acute hepatitis, we have found high and homogenous correlation in the IgM type immune responses against all the examined HBxAg regions. Moreover, strong correlation has been observed between IgG type immune responses to a characteristic C-terminal region (C1: 79-117) and the longest fragment (X: 10-143). Moderate correlation has been found between HBxAg concentration and the IgG type anti-HBx antibody levels against C-terminus of HBxAg in patients with chronic hepatitis. In the case of symptomless carriers, there were also demonstrable associations in the immune responses against the C-terminal sequences; however, significant correlations were found for antibody production against the N-terminal region as well. The examinations show that the C-terminal sequence, responsible for transactivation, promotes an efficient IgG antibody response in all three groups of patients, whereas the negative regulator N-terminal part of the HBxAg molecule for the most part does not trigger antibody production. This suggests that the immune responses against various - biologically active - epitopes of the HBxAg may have a different role in the pathogenesis of hepatitis and may be used as prognostic markers in human HBV infections.
Pál
József
J
Department of Immunology and Biotechnology, University of Pécs, Faculty of Medicine, Pécs, H-7643, Hungary.
Nyárády
Zoltán
Z
Marczinovits
Ilona
I
Pár
Alajos
A
Ali
Younes Saleh
YS
Berencsi
György
G
Kvell
Krisztián
K
Németh
Péter
P
D000595:Amino Acid Sequence; D000918:Antibody Specificity; D004797:Enzyme-Linked Immunosorbent Assay; D006509:Hepatitis B / Q000097:blood* / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006801:Humans; D008969:Molecular Sequence Data; D011379:Prognosis; D011994:Recombinant Proteins / Q000276:immunology; D012044:Regression Analysis; D017386:Sequence Homology, Amino Acid; D015534:Trans-Activators / Q000097:blood* / Q000235:genetics / Q000276:immunology; D054334:Viral Regulatory and Accessory Proteins
D006510:Hepatitis B Antibodies; D011994:Recombinant Proteins; D015534:Trans-Activators; D054334:Viral Regulatory and Accessory Proteins; C057628:hepatitis B virus X protein